Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

NEW YORK – Adaptive Biotechnologies today announced a partnership with AbbVie to use next-generation sequencing-based minimal residual disease testing in multiple myeloma drug trials.

Under the terms of the multi-year, global collaboration agreement, AbbVie will use Adaptive's clonoSeq assay to assess MRD status in response to venetoclax across multiple clinical trials. The partners will evaluate the depth and duration of response to venetoclax by using clonoSeq to measure and monitor MRD negativity in treated patients.

Financial and other details of the agreement were not disclosed.

"Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma," Chad Robins, Adaptive Biotechnologies CEO and cofounder, said in a statement. "This partnership supports the growing use of clonoSeq in drug development as an accurate, reliable method to assess response to new treatments that can meaningfully improve patient care."

Venetoclax is a small molecule selective B cell lymphoma-2 inhibitor AbbVie is developing to treat multiple myeloma. Adaptive's clonoSeq assay is an FDA-authorized test for MRD detection in multiple myeloma and acute lymphoblastic leukemia using bone marrow samples.

Adaptive also has collaborations to assess MRD in multiple myeloma drug trials with Sanofi, for isatuximab, and with Amgen, for the combination of carfilzomib (Kyprolis) and daratumumab (Janssen's Darzalex). The Seattle-based firm also has partnerships with Genentech and Argos Therapeutics.